OPCH: Growth in acute and specialty therapies, portfolio diversification, and new rare drugs drive momentum
Momentum has stabilized with growth in acute and specialty therapies, supported by a diversified portfolio and strong hospital partnerships. Biosimilar competition and new rare therapies are expected to drive future growth, while regulatory changes and capital allocation remain focused on expanding…